Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15893479 | 0.87 | POLB (0.48) | HPGDALDH1A1KMT2ARAB9APOLB | |
| SCHEMBL15868268 | 0.83 | SIGMAR1 (0.40) | SIGMAR1HPGDALDH1A1KMT2ARAB9A | |
| SCHEMBL14751534 | 0.76 | SIGMAR1 (0.41) | SIGMAR1HPGDALDH1A1KMT2ARAB9A | |
| SCHEMBL18089666 | 0.73 | SMN1; SMN2 (0.40) | SIGMAR1HPGDALDH1A1KMT2ARAB9A | |
| SCHEMBL15893484 | 0.73 | PSEN1 (0.38) | SIGMAR1HPGDALDH1A1KMT2ARAB9A | |
| SCHEMBL17349747 | 0.73 | MEN1 (0.44) | HPGDALDH1A1KMT2ARAB9APOLB | |
| SCHEMBL17286470 | 0.71 | SIGMAR1 (0.42) | SIGMAR1HPGDALDH1A1KMT2ARAB9A | |
| SCHEMBL18662417 | 0.71 | SIGMAR1 (0.42) | SIGMAR1HPGDALDH1A1KMT2ARAB9A | |
| SCHEMBL17349751 | 0.71 | NPC1 (0.48) | HPGDALDH1A1KMT2ARAB9APOLB | |
| SCHEMBL14751697 | 0.70 | HPGD (0.41) | SIGMAR1HPGDALDH1A1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119363-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | Rempex Pharmaceuticals, Inc.. (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119363-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | Rempex Pharmaceuticals, Inc.. (US) | 2015-04-30 | — | — | US | disclosed |
| US-9012491-B2 | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012491-B2 | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140206648-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206648-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2013122888-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | REMPEX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013033461-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206648-A1 | HETEROCYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BTD | SIGMAR1 2173/4885HPGD 1174/4885ALDH1A1 2081/4885 |
| US-20150119363-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | MMP8, ELANE, LCT | SIGMAR1 3883/4885HPGD 615/4885ALDH1A1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.